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The cancer-associated cell 
migration protein TSPAN1 is 
under control of androgens and its 
upregulation increases prostate 
cancer cell migration
Jennifer Munkley1, Urszula L. McClurg2, Karen E. Livermore1, Ingrid Ehrmann1, Bridget 
Knight3, Paul Mccullagh4, John Mcgrath5, Malcolm Crundwell6, Lorna W. Harries7, Hing Y. 
Leung8,9, Ian G. Mills10,11,12, Craig N. Robson2, Prabhakar Rajan13 & David J. Elliott1
Cell migration drives cell invasion and metastatic progression in prostate cancer and is a major cause of 
mortality and morbidity. However the mechanisms driving cell migration in prostate cancer patients are 
not fully understood. We previously identified the cancer-associated cell migration protein Tetraspanin 
1 (TSPAN1) as a clinically relevant androgen regulated target in prostate cancer. Here we find that 
TSPAN1 is acutely induced by androgens, and is significantly upregulated in prostate cancer relative 
to both normal prostate tissue and benign prostate hyperplasia (BPH). We also show for the first time, 
that TSPAN1 expression in prostate cancer cells controls the expression of key proteins involved in 
cell migration. Stable upregulation of TSPAN1 in both DU145 and PC3 cells significantly increased cell 
migration and induced the expression of the mesenchymal markers SLUG and ARF6. Our data suggest 
TSPAN1 is an androgen-driven contributor to cell survival and motility in prostate cancer.
Cancer, in its most aggressive form, is not only a disease of uncontrolled cell growth, but also a disease of inap-
propriate cell migration. Activating invasion and metastasis is a hallmark of cancer progression1, 2 and is the 
leading cause of mortality among cancer patients3. Metastasis involves cancer cells detaching from the primary 
tumour, and travelling as circulating tumour cells through the bloodstream or lymphatic system to other parts of 
the body. Prostate cancer is the most common male cancer in Europe, with around 50,000 new cases in the UK 
each year4. At initial diagnosis 37–43% of men have late stage disease and 17–34% of prostate cancer patients have 
metastasis (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/
prostate-cancer/incidence#ref-8). The development of prostate cancer is initially driven by androgen steroid hor-
mones via the androgen receptor (AR) transcription factor. The first line treatment for prostate cancer that is no 
longer organ confined is androgen deprivation therapy (ADT). However, after 2–3 years many patients develop 
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castrate resistant prostate cancer (CRPC) for which treatment options are limited and prognosis is poor5, mean-
ing there is an urgent need to develop new treatments for advanced prostate cancer. Prognostic heterogeneity is 
an important feature of prostate cancer; while some prostate cancers can progress very rapidly, others can remain 
indolent for many years, hence there also a major unmet clinical need to identify new biomarkers to help distin-
guish indolent from aggressive disease6.
The mechanisms underlying the development and progression of prostate cancer are poorly understood. We 
recently used RNA-Sequencing to comprehensively profile how the prostate cancer transcriptome responds to 
androgens7. Our approach directly correlated gene expression data from LNCaP cells before and after androgen 
exposure, with data from a small cohort of 7 prostate cancer patients before and after ADT. We identified a set 
of nearly 700 genes which were reciprocally regulated between the two datasets and so were strong candidates to 
be clinically relevant androgen-regulated genes in prostate cancer. This set of 700 genes included the gene for the 
cancer-associated cell migration protein Tetraspanin 1 (TSPAN1) which had not previously been shown to be 
regulated by androgens in prostate cancer.
Tetraspanins, also known as the transmembrane 4 superfamily, are small transmembrane glycoproteins which 
were first described in studies of tumour associated proteins8–13. As a member of the tetraspanin family, TSPAN1 
has been reported to regulate cancer progression in many human cancers. TSPAN1 is upregulated in human 
hepatocellular carcinoma14, gastric carcinoma15, colorectal adenocarcinoma16, ovarian carcinomas17 and cervical 
cancer18, 19. Tetraspanins reportedly play a role in a range of biological processes including cell proliferation9, cell 
adhesion20, cell migration and motility21, 22 and signal transduction23, 24. Here, we show that expression of TSPAN1 
is controlled by androgens in prostate cancer cells, is upregulated in prostate cancer tissue and is important for 
prostate cancer cell survival and migration. Our findings are in agreement with numerous studies showing that 
TSPAN1 is upregulated in several other cancer types15, 17, 25–28, but are in contrast to a recent publication suggest-
ing that decreased TSPAN1 is linked to prostate cancer progression29.
Results
TSPAN1 is an early target of the AR in vitro and in vivo. Previous RNA-Seq analysis of LNCaP cells 
identified the cancer-associated TSPAN1 gene as being under control of androgens after 24 hours treatment with 
10 nM of the synthetic androgen analogue R1881 (methyltrienolone)7. Using a time course and real-time PCR 
we found that androgen mediated induction of the TSPAN1 gene could be detected in LNCaP cells 9 hours after 
androgen exposure suggesting it is directly regulated by the AR. The early expression profile of TSPAN1 follow-
ing androgen exposure had similar dynamics to the known directly AR-regulated gene KLK3 (PSA) (Fig. 1A). 
Androgen-mediated induction of TSPAN1 expression in LNCaP cells was also induced by treatment with a range 
of R1881 concentrations for 24 hours, consistent with TSPAN1 induction also occurring under physiological 
androgen concentrations within the prostate (Fig. 1B), and was blocked by treatment with the AR antagonist 
CasodexR (bicalutamide) (Fig. 1C). To test whether androgen-mediated induction of TSPAN1 expression was 
a result of AR activity, we treated LNCaP cells with 10 mM R1881 (androgens) in the presence and absence of 
cycloheximide to inhibit de novo protein synthesis. Androgen mediated up-regulation of TSPAN1 mRNA expres-
sion was observed in the presence or absence of the protein synthesis inhibitor cycloheximide indicating that 
TSPAN1 induction might be directly mediated by the AR (Fig. 1D). Consistent with this, analysis of previously 
published AR ChIP-Seq data30 revealed an AR binding site which is overlapping with the start of the TSPAN1 
gene for both LNCaP and VCaP cells (Supplementary Figure 1).
Expression of TSPAN1 protein was also induced by treatment of LNCaP cells with 10 nM R1881 (Fig. 1E). 
Confirming this effect on protein levels was mediated by the AR, we found that androgen-mediated induction of 
the TSPAN1 protein is prevented when cells are depleted of the AR using esiRNA (Fig. 1F). Interestingly, although 
induction of TSPAN1 mRNA was detected within 9 hours of androgen exposure, induction at the protein level 
was not detected until 48 hours. Specificity of our TSPAN1 antibody was confirmed via siRNA mediated protein 
depletion and detection of over-expressed protein by western blotting (Supplementary Figure 2A,B). Supporting 
our data obtained in LNCaP cells, TSPAN1 expression was also androgen responsive in VCaP cells at both the 
RNA and protein level (Fig. 1G). Analysis of previously published RNA-Seq data from before and after 7 days 
of androgen depletion in prostate cancer patients using Degarelix31 shows a significant reduction in TSPAN1 
mRNA indicating a tissue based response (Fig. 1H). Similarly, analysis of previously published RNA-Seq data 
from 7 prostate cancer patients32 showed that TSPAN1 gene expression is strongly down-regulated following 
ADT (Fig. 1I), suggesting that TSPAN1 is also regulated (either directly or indirectly) by androgens in vivo within 
patients.
TSPAN1 is upregulated in prostate cancer tissue. We carried out meta-analysis of 1012 prostate tissue 
samples using data from 14 previously published studies33–46 to monitor how expression of TSPAN1 changes in 
clinical prostate cancer. We found that 11/14 datasets showed significant up-regulation of TSPAN1 mRNA expres-
sion in prostate carcinoma versus normal prostate tissue (Supplementary Table 1). TSPAN1 expression showed an 
average mean fold change of 2.214 (p = 1.31E-6) in 122 primary prostate carcinoma samples studied by Grasso et 
al.33, and a mean fold change of 1.844 (p = 1.72E-7) in 185 samples studied by Taylor et al.34. TSPAN1 expression 
analysis by real-time PCR showed that TSPAN1 mRNA was significantly up-regulated in prostate carcinoma 
samples relative to BPH samples (p = 0.049), and in primary prostate tumour tissue relative to matched normal 
tissue from the same patient (p = 0.0004) (Fig. 2A,B).
To develop a rigorous test for TSPAN1 protein we extensively validated our TSPAN1 antibody in multiple 
cell lines using western blotting, siRNA mediated protein depletion, and detection of over-expressed protein 
(Supplementary Figure 2A,B). To examine TSPAN1 protein expression in clinical prostate cancer tissue we fur-
ther showed that staining by this antibody was blocked by pre-incubation with a blocking peptide (Supplementary 
Figure 2C) and by detection of siRNA mediated protein depletion by immunohistochemistry in Formalin Fixed 
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Figure 1. TSPAN1 is regulated by androgens in in vitro and in vivo. (A) Analysis of TSPAN1 and KLK3 (PSA) 
mRNA in LNCaP cells treated with androgens (A+) over a 24 hour time course. (B) Upregulation of TSPAN1 
is also evident in LNCaP cells treated with 1 to 100 nM of R1881. (C) Induction of TSPAN1 mRNA by the AR 
is inhibited in the presence of 10 μM of the anti-androgen Casodex (bicalutamide) (lane 6). (D) The increase 
in TSPAN1 mRNA expression in response to androgens is still seen in the presence of 1 μg/ml cycloheximide 
(CHX). Relative TSPAN1 expression was detected by real-time PCR and normalised to three reference genes. 
(E) Expression of TSPAN1 protein is induced in LNCaP cells treated with 10 nM R1881 for 48 hours as detected 
by western blot. Actin was used as a loading control. (F) Depletion of AR protein in LNCaP cells by esiRNA 
shows that when the AR is depleted there is no induction of the TSPAN1 protein in response to androgens. 
(G) Real-time PCR and western blot analysis of TSPAN1 mRNA and protein in VCaP cells grown in steroid 
deplete (SD) or 10 nM R1881 (androgens, A+) treated conditions for 48 hours. (H) Analysis of TSPAN1 
mRNA expression before and after 7 days of serum/tissue androgen depletion in prostate cancer patients using 
degarelix31. (I) Analysis of TSPAN1 expression in previously published RNA-Seq data32 shows that TSPAN1 
mRNA is significantly down-regulated in 7 PCa patients following androgen deprivation treatment (ADT). The 
Y axis shows the relative expression level of TSPAN1 (calculated by comparing the FPKM expression values of 
genes after ADT to the value before treatment). Please note: cropped western blots are displayed in the figure, 
but full length blots are included in the Supplementary Information file.
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Paraffin Embedded (FFPE) cell pellets (Supplementary Figure 2D). TSPAN1 is predicted to be a transmembrane 
protein (http://www.uniprot.org/uniprot/O60635#subcellular_location), and the localisation of TSPAN1 within 
prostate tissue was mainly cytoplasmic and membrane bound. Staining a tissue microarray (TMA) containing 
26 samples from patients with BPH and 72 samples from patients with prostate cancer confirmed that TSPAN1 
protein is also expressed at significantly higher levels in prostate cancer patients compared to benign controls 
(p = 0.0081) (Fig. 2C) (further information on the clinical samples used in the TMA is given in Supplementary 
Table 2). Representative cores from each TMA are shown in Fig. 2D.
Figure 2. TSPAN1 is upregulated in prostate cancer tissue. (A) Real-time PCR analysis of TSPAN1 mRNA from 
normal and matched prostate cancer tissue from 9 patients obtained from radical prostatectomy. (B) We also 
analysed 32 benign samples from patients with benign prostate hyperplasia (BPH) and 17 malignant samples 
from transurothelial resection of the prostate (TURP) samples. (C) Analysis of TSPAN1 protein levels in 
patients with BPH or prostate cancer by Tissue Microarray (TMA). (D) Representative cores from each TMA. 
(E) TSPAN1 gene expression levels in prostate tissue from the primary or metastatic site in data published by 
Grasso et al.33.
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A previous study suggested decreased TSPAN1 could be used to predict biochemical recurrence after radical 
prostatectomy29, however, our data indicates no significant correlation between both overall survival and relapse 
free survival for patients with either low or high TSPAN1 (Supplementary Figure 3). To determine whether 
TSPAN1 is associated with cancer metastasis, we studied TSPAN1 gene expression in prostate cancer tissue 
obtained from either the primary or metastatic site using a previously-published clinical dataset33. We observed 
a changing pattern of TSPAN1 expression between primary and metastatic tumours with a striking decrease in 
TSPAN1 expression in prostate cancer tissue from the metastatic site (p = 5.26E-21) (Fig. 2E).
TSPAN1 increases prostate cancer cell migration and can upregulate expression of Slug and 
ARF6. The above data indicated that prostate cancer cells over-express TSPAN1 compared to normal or benign 
prostate tissue. To investigate why upregulation of TSPAN1 might be important in prostate cancer cells, we cre-
ated DU145 and PC3 cell lines that over-express TSPAN1 protein (Fig. 3A,C). DU145 and PC3 cells were chosen 
for these analyses as they have low endogenous TSPAN1 levels (Supplementary Figure 4). Although there were no 
significant differences in cell proliferation or adhesion with upregulated TSPAN1 (Supplementary Figure 5), the 
rate of cell migration was significantly increased in both DU145 and PC3 cell backgrounds (Fig. 3B,D).
To probe the regulatory mechanism governing TSPAN1-dependent prostate cancer cell motility, we ana-
lysed expression of 77 genes with established roles in the epithelial to mesenchymal transition (EMT) and/or cell 
motility and migration. In DU145 cells 10 out of 77 genes showed significant changes in gene expression when 
TSPAN1 was overexpressed (Supplementary Table 3), including genes associated with EMT. Increased expres-
sion of the EMT-related transcriptional repressor Slug and the small GTP-binding protein ARF6 was also seen 
at the protein level (Fig. 3E), and in PC3 cells with upregulated TSPAN1 (Fig. 3F). Slug expression is increased 
in advanced-stage primary prostate cancer where it has been shown to play a role in the EMT transition47. Slug 
is also highly expressed in prostate cancers associated with a neuroendocrine phenotype48. Consistent with this, 
Figure 3. TSPAN1 increases prostate cancer cell migration and induces the expression of Slug and ARF6. 
(A,C) Validation of TSPAN1 overexpression in DU145 and PC3 cells by real-time PCR and western blot. (B,D) 
Migration assays for DU145 and PC3 cells overexpressing TSPAN1. (E,F) Western blot analysis of Slug and 
ARF6 protein expression in DU145 and PC3 cells overexpressing TSPAN1. Please note: cropped western blots 
are displayed in the figure, but full length blots are included in the Supplementary Information file.
www.nature.com/scientificreports/
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using data generated by Beltran et al.49 we found TSPAN1 and Slug are co-amplified in 28% and 37% of neuroen-
docrine prostate cancer tumours respectively (Supplementary Table 4).
TSPAN1 is essential for prostate cancer cell viability. Previous studies on other cancer cell types have 
indicated that TSPAN1 can be essential for cell survival and proliferation28, 50, 51. To test whether changes in the 
expression of TSPAN1 can influence prostate cancer cell viability, we depleted LNCaP and CWR22RV1 cells 
of TSPAN1 protein using two independent siRNAs. Loss of TSPAN1 resulted in a significant reduction in cell 
number and significantly reduced cell viability for both cell lines 96 hours after siRNA treatment (Fig. 4A,B). To 
examine whether TSPAN1 is upstream of key cell signalling pathways in prostate cancer, we tested whether deple-
tion of TSPAN1 influenced PIK3 signalling (detected using phospho-AKT) or RAS/ERK1/2 signalling (detected 
using phospho-ERK1/2). We observed a significant reduction in the levels of phospho-ERK1/2 levels in both 
LNCaP and CWR22RV1 cells in LNCaP cells with depleted TSPAN1, but there was no difference in the levels of 
phospho-AKT (Fig. 4C,D).
Discussion
The progression to advanced prostate cancer is thought to involve persistence of AR signalling, and prostate can-
cer treatment is dominated by strategies to control AR activity52. The AR controls prostate cancer development 
through the regulation of transcription, meaning that identifying both transcriptional targets of the AR and the 
factors involved will provide opportunities for both cancer detection and therapeutic intervention. Here, we show 
that the Tetraspanin 1 gene (TSPAN1) is regulated by androgens and is significantly upregulated in primary pros-
tate cancer tissue. We find that while normal expression of TSPAN1 is important for prostate cancer cell viability, 
induced upregulated expression drives increased cell migration. The data presented in this study are in contrast to 
a recent publication suggesting that decreased TSPAN1 is linked to prostate cancer progression and that TSPAN1 
plays a negative role in prostate cancer cell proliferation and migration (which used a different antibody to detect 
TSPAN129), but are in agreement with studies in numerous other cancer types where upregulated TSPAN1 is 
linked to cancer progression, cell survival, proliferation, migration and invasion15, 17, 25–28, 50, 51, 53.
Tetraspanins are reported to play a role in a range of biological processes including cell proliferation9, cell 
adhesion20, cell migration and motility11, 21, 22 and signal transduction23, 24. Previous studies have indicated that 
tetraspanins can regulate the function of proteins involved in all aspects of cell migration11. For example, tet-
raspanins can directly interact with integrins and modulate their downstream signalling in response to migratory 
signals54, 55. Tetraspanin CD9 has been shown to regulate expression of MMP9 via the JNK pathway56, 57, and 
tetraspanin CD82 can inhibit cancer cell retraction and motility via deregulation of the Rac1/RhoA signaling 
network58, 59. Tetraspanins also play a role in E-cadherin based cell–cell junctions60–62, and can directly interact 
with and influence the activity of matrix metalloproteinases63, 64.
TSPAN1 has been shown to promote invasiveness of cervical cancer cells27, increase the proliferation and 
invasion of colon cancer cells in vitro50, promote survival and invasion of skin carcinoma cells51, and to play a 
role in survival, proliferation and carcinogenesis of pancreatic cancer28. In addition, regulation of TSPAN1 by 
micro-RNAs has been shown to promote cell proliferation and invasion in colorectal cancer65, and cell migra-
tion in non-small cell lung cancer26. Taken together, these studies suggest a positive role for TSPAN1 in cancer 
progression, but the mechanisms underlying this are currently poorly understood. Here, we find for the first 
time, that TSPAN1 expression controls the expression of key proteins with roles in cell migration. We show that 
upregulation of TSPAN1 in prostate cancer cells results in increased expression of the zinc finger transcription 
factor Slug (SNAI2) which has previously been shown to promote migration and invasion, and a transition to a 
more mesenchymal state in prostate cancer cells47, 66. Slug expression is increased in advanced primary prostate 
tumours47, and clusters in cancer cells at the invasive front in neuroendocrine areas of high-grade prostate can-
cer48. TSPAN1 also modulates the expression of small GTPase ADP-ribosylation factor 6 (ARF6) which is linked 
to cancer cell motility67, and is upregulated in prostate cancer tissue68. To the best of our knowledge this is the 
first time these genes have been shown to be regulated by TSPAN1 in any cancer type. Inhibition of TSPAN1 in 
prostate cancer has been previously linked with increased phosphorylation of AKT29, however we found no evi-
dence of this in our study. A study in cervical cancer excluded a role for TSPAN1 in focal adhesion kinase (FAK), 
phosphoinositide-3-kinase (PI3K) and in EGFR-dependent signalling to the RAS/ERK pathway, arguing against 
a role for TSPAN1 as a mediator of cell surface receptor signalling27.
By identifying a mechanism through which this protein can modulate cell migration this current study thus 
sheds new light on the role of TSPAN1 in cancer. EMT and MET are processes by which cells transit between 
epithelial and mesenchymal states and play an integral role in cancer metastasis69. Activation of EMT is important 
for cancer cell dissemination, whereas the reversal of EMT (or MET) is necessary for efficient metastatic coloni-
sation70, 71. Taken together our data suggest dynamic TSPAN1 expression levels might contribute to transitions 
between a more migratory mesenchymal like cell phenotype and establishing stable metastases. We find TSPAN1 
expression in prostate cancer is biphasic, with upregulation at the primary site and downregulation in metastatic 
lesions. Similarly, a study in breast cancer has shown that although TSPAN1 is upregulated in most primary 
tumours it is more likely to be downregulated in metastatic lesions72.
TSPAN1 is part of a larger gene family. It has been speculated that distinct combinations of tetraspanins could 
act in concert to control various aspects of cell behaviour in cancer cells27. Tetraspanin CD151 is elevated in 
patients with prostate cancer73 and has been shown to contribute to spontaneous metastasis in mouse models74. 
TSPAN8 is also upregulated in prostate cancer tissue and associated with cell invasion75. Conversely, tetraspanin 
CD9 is downregulated during prostate cancer progression76 and is a suppressor of metastasis in prostate cancer 
mouse models77. Prostate cancer is an extremely heterogeneous disease and it is likely that the role of tetraspanins 
is multifaceted in the development and progression of prostate cancer. Interestingly, TSPAN1 is listed in the top 
30 most common and abundant glycoproteins detected in prostate cancer secretions by mass spectrometry and 
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has been studied as part of a predictive signature for prostate cancer aggressiveness78, 79. The overlapping TMA 
data for TSPAN1 between benign and prostate cancer groups presented in this study do not suggest that detection 
of TSPAN1 alone could be used clinically, but indicate it may still be worthwhile to examine TSPAN1 levels as 
part of a ‘tetraspanin signature’ in future studies.
Figure 4. TSPAN1 is essential for prostate cancer cell viability. Depletion of TSPAN1 in (A) LNCaP and (B) 
CWR22 RV1 cells by transient transfection with siRNA. Protein depletion was carried out using two different 
siRNAs in cells grown in full media. 96 hours after transfection knockdown of TSPAN1 was confirmed by 
real-time PCR and western blot and the relative number of live cells was calculated. Representative crystal 
violet stained images are shown below for each cell line after 7 days (due to a dramatic decrease in cell viability 
we were unable to harvest enough live cells to confirm TSPAN1 knockdown after 96 hours). (C) Western blot 
analysis of various proteins in LNCaP and (D) CWR22 RV1 cells following siRNA mediated protein depletion 
of TSPAN1 for 96 hours. Please note: cropped western blots are displayed in the figure, but full length blots are 
included in the Supplementary Information file.
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In conclusion, our study shows that expression of TSPAN1 is controlled by androgens in prostate cancer 
cells and is upregulated in prostate cancer tissue. The AR has been shown to be essential for prostate cancer cell 
viability, proliferation and invasion80–82, however the mechanisms controlling this are poorly understood. Our 
data supports TSPAN1 as an androgen-driven contributor to prostate cancer cell survival and motility, which can 
control the expression of the mesenchymal proteins Slug and ARF6. Future studies will help elucidate the role 
TSPAN1 plays in these processes in relation to other AR regulated genes and whether TSPAN1 can be targeted 
therapeutically.
Methods
Cell Culture. Cell culture and the treatment of cells with androgens were as described previously7, 83–86. LNCaP 
cells (CRL-1740, ATCC) were maintained in phenol red free RPMI-1640 with L-Glutamine (PAA Laboratories, 
R15–802) supplemented with 10% Fetal Bovine Serum (FBS) (PAA Laboratories, A15-101). For androgen treat-
ment of LNCaP cells, medium was supplemented with 10% dextran charcoal stripped FBS (PAA Laboratories, 
A15-119) to produce a steroid-deplete medium. Following culture for 72 hours, 10 nM synthetic androgen ana-
logue methyltrienolone (R1881) (Perkin–Elmer, NLP005005MG) was added (Androgen+) or absent (Steroid 
deplete) for the times indicated. Stable cell lines were generated by transfecting cells using Lipofectamine 2000 
(11668-027, Invitrogen), followed by selection with 300 µg/ml Geneticin (Invitrogen, 10131019) (reduced to 
150 µg/ml following the death of untransfected cells) for at least four weeks.
siRNA. Knockdown of TSPAN1 was carried out using predesigned siRNA sequences purchased from IDT 
(hs.Ri.TSPAN1.13.1 and hs.Ri.TSPAN1.13.2). AR esiRNA was obtained from Sigma-Aldrich (EHU025951). 
Transfections were carried out using LipofectamineR RNAi Max (Thermo Fisher Scientific 13778075) as per the 
manufacturer’s instructions.
RT-qPCR. Cells were harvested and total RNA extracted using TRI-reagent (Invitrogen, 15596-026), accord-
ing to the manufacturer’s instructions. RNA was treated with DNase 1 (Ambion) and cDNA was generated by 
reverse transcription of 200ng of total RNA using the Superscript VILO cDNA synthesis kit (Invitrogen, 11754-
050). Quantitative PCR (qPCR) was performed in triplicate on cDNA using SYBR® Green PCR Master Mix 
(Invitrogen, 4309155) using the QuantStudio™ 7 Flex Real-Time PCR System (Life Technologies). Gene expres-
sion changes were analysed using relative quantification (comparative CT method) to a given control sample. 
Samples were normalised using the average of three reference genes: GAPDH, β –tubulin and actin. All primer 
sequences are listed in Supplementary Table 5.
Antibodies. The following antibodies were used in the study: anti-TSPAN1 antibody produced in rabbit 
(Sigma-Aldrich HPA011909), anti-AR mouse antibody (BD Bioscience, 554226), anti-p21 Waf1/Cip1 rabbit 
antibody (Cell Signaling 2947), anti-slug rabbit antibody (Cell Signaling 9585), anti- phospho-p44/42 MAPK 
mouse monoclonal (Erk1/2 Thr202/Tyr204) (Cell signaling 9106), anti-ERK2 mouse monoclonal (1647 Santa 
Cruz), anti-AKT rabbit antibody (Santa Cruz, sc-8312), anti-phospho-AKT1 (pSer473) rabbit antibody (Sigma, 
SAB4300042), anti-ARF6 rabbit antibody (Cell Signaling 5740), anti-FLAG mouse monoclonal (F3165, Sigma), 
anti-actin rabbit polyclonal (A2668, Sigma), normal rabbit IgG (711-035-152 Jackson labs) and normal mouse 
IgG (715-036-150 Jackson labs). Quantifications of western blots were carried out using ImageJ. Pixel densities 
for the bands of interest were calculated relative to background levels and the normalising control (actin). The 
concentrations of antibodies used are given in Supplementary Table 6.
DNA Constructs. For stable transfection of DU145 and PC3 cells TSPAN1 was cloned into pX3flag CMV 
10 (E7658, Sigma) using EcoR1 and Xba1. The plasmid used underwent DNA sequencing to confirm correct 
insertion of the TSPAN1 gene.
Cell Viability Assay. Cell viability analysis was carried out using the TaliR Cell Viability Kit (Life 
Technologies A10786) and the TaliR Image-based Cytometer. Relative cell numbers following siRNA treatment 
were determined using the TaliR Image-based Cytometer (Life Technologies).
Migration Assays. Cell migration assays were carried out using the collagen coated OrisTM Pro Cell 
Migration Assay (Platypus Technologies PROCMACC1) as per the manufacturer’s instructions. For both DU145 
and PC3 cells 30,000 cells per well were seeded at the start of the experiment. The results presented show the rel-
ative migration for each cell line over 41 hours (DU145 cells) or 30 hours (PC3 cells).
Adhesion Assays. For adhesion assays cells were labelled with 5 µM Calcein-AM (BD Biosciences). 50,000 
cells were then allowed to adhere to collagen coated plates for two hours, washed 4 times with PBS (to remove any 
non-adherent cells), and the absorbance measured at 485/538 nm using a plate reader. The percentage adhesion 
was then calculated by comparing a washed plate (representative of the number of adherent cells) to an identical 
unwashed plate (representative of the total number of cells seeded).
Immunohistochemistry. A tissue microarray (TMA) containing 0.6 mm cores of benign prostatic hyper-
plasia (BPH) (n = 26), PC (n = 72), and control tissues including breast, kidney, placenta, ovary, and liver was 
used87. A specialised urological pathologist selected representative tissue pieces to be included in the TMA based 
on percentage of tumours cells assessed from the H&E stained sections. For each patient two separate represent-
ative areas were selected and included on the TMA to account for tumour heterogeneity. Antigen retrieval was 
performed by pressure cooking the TMA for 90 seconds in 10 mM citrate pH 6.0 followed by staining the tissues 
with anti-TSPAN1 antibody (Sigma-Aldrich HPA011909) at a 1:1500 dilution. Nuclei were counterstained with 
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 5249  | DOI:10.1038/s41598-017-05489-5
haematoxylin. The TMA was scored by Urszula L. McClurg using the 0-300 Histoscore score method88. Only epi-
thelial cells were scored. Sections were scored based on their staining intensity with 0 being assigned to cells with 
absent staining, 1 to weak staining, 2 to moderate staining and 3 to strong staining. Within each staining intensity 
percentage of epithelial cells (0–100%) with this staining intensity was assigned. This resulted in a Histoscore 
calculated from the following equation H = 0x (% of cells scored at 0) + 1x (% of cells scored at 1) + 2x (% of cells 
scored at 2) + 3x (% of cells scored at 3).
Clinical Samples. Our study made use of RNA from 32 benign samples from patients with benign pros-
tatic hyperplasia (BPH) and 17 malignant samples from transurethral resection of the prostate (TURP) samples. 
Malignant status and Gleason score were obtained for these patients by histological analysis. We also analysed 
normal and matched prostate tissue from 9 patients obtained by radical prostatectomy. The samples were obtained 
with ethical approval through the Exeter NIHR Clinical Research Facility tissue bank (Ref: STB20). Our TMA 
study made use of 26 BPH and 72 prostate cancer tissue samples. These samples were obtained with full ethi-
cal approval from the Northumberland, Tyne and Wear NHS Strategic Health Authority Local Research Ethics 
Committee (Ref: 2003/11). Written informed consent for the use of surgically obtained tissue was provided by all 
patients. All methods were performed in accordance with the relevant guidelines and regulations.
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